



xTAG[®] Cystic Fibrosis 39 Kit v2
xTAG[®] Cystic Fibrosis 71 Kit v2
The broadest choice in
CFTR mutation coverage

Luminex[®]

Choose your assay. Choose your coverage

xTAG® Cystic Fibrosis (CFTR) 39 Kit v2*

ΔF508	A455E	R1162X	1078delT	1898+5G>T
ΔI507	1717-1G>A	3659delC	394delTT	2183AA>G
G542X	R560T	3849+10kbC>T	Y122X	2307insA
G85E	R553X	W1282X	R347H	Y1092X
R117H	G551D	N1303K	V520F	M1101K
621+1G>T	1898+1G>A	5/7/9T	A559T	S1255X
711+1G>T	2184delA	F508C	S549N	3876delA
R334W	2789+5G>A	I507V	S549R	3905insT
R347P	3120+1G>A	I506V		

ACMG recommended mutations*
* Genet Med. 2004 Sep-Oct; 6(5):387-91.

+

xTAG® Cystic Fibrosis (CFTR) 71 Kit v2*

CFTRdele2,3	G330X	3791delC
E60X	R352Q	Q890X
R75X	S364P	2869insG
405+3A>C	G480C	3120G>A
406-1G>A	Q493X	3199del6
444delA	1677delTA	R1066C
R117C	1812-1G>A	W1089X
G178R	G622D	D1152H
L206W	2055del9>A	R1158X
935delA	2143delT	S1196X
ΔF311	K710X	

Broad Ethnic Coverage

16 most common additional mutations recommended mutations covered
Accuracy of 100% for genotyping information used for carrier and newborn screening

List of mutations or variants identified in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene.
*CE-IVD and Licensed for diagnostic use in Canada.

Ethnic Group	Incidence of CF*	CF MUTATION DETECTION RATE (%)*		
		ACMG* RECOMMENDED MUTATIONS ONLY	xTAG® Cystic Fibrosis (CFTR) 39 Kit v2	xTAG® Cystic Fibrosis (CFTR) 71 Kit v2
Caucasian	1 in 3,200	88.29	89.66	91.13
Hispanic Americans	1 in 9,500	71.72	73.36	83.77
African Americans	1 in 15,300	64.46	68.56	76.94
Ashkenazi Jewish	1 in 3,300	94.04	94.04	95.94
Asian American	1 in 32,100	48.93	54.53	54.53

* Data collected from the following references: Watson et al. (2004) Genet Med 6(5):387-91.; Richards et al. (2002) Genet Med 4(5):379-391.; Bobadilla et al. (2002) Human Mutat 19:575-606.; Heim et al. (2001) Genet Med 3:168-76.; Sugarman et al. (2004) Genet Med 6:392-99.; Organ et al. (2001) Genet Testing 5:47-52.; Wong et al. (2001) Human Mutat 18:296-307.; Alder et al. Human Mutat 2004 MIB #752; Shriver et al. (2005) JMD 7:289-99.

The benefits of xTAG® Cystic Fibrosis Assays:

Comprehensive: Most comprehensive mutation coverage, including ACMG/ACOG recommended panel.

Flexibility: Mutation panel selection through the software.

Confidence: Second generation of IVD assay with 100% overall Accuracy and >99% Precision.

Ease of Use: Streamlined protocol with minimal hands-on time. All ancillary reagents and enzymes included.

Cost-effective: Multiplex genotyping - No reflex testing necessary.

Kit	Catalog #
xTAG Cystic Fibrosis (CFTR) 39 kit v2	1027C0232
xTAG Cystic Fibrosis (CFTR) 71 kit v2	1024C0185

For more Information, visit the Luminex website at www.luminexcorp.com.

For sales and product information, call 1-800-593-2370 or email info@luminexcorp.com

UNITED STATES
Luminex Corporation
Austin, Texas
Tel: 512.219.8020
Fax: 512.219.5195

CANADA
Luminex Molecular Diagnostics
Toronto, Ontario
Tel: 416.593.4323
Fax: 416.593.1066

EUROPE
Luminex B.V.
Oosterhout, The Netherlands
Tel: +31.162.408333
Fax: +31.162.408337

CHINA
Luminex Shanghai Trading Co.
Shanghai, China
Tel: +21.616.50809
Fax: +21.616.50811

JAPAN
Luminex Japan Corporation, Ltd.
Tokyo, Japan
Tel: +81.3.5545.7440
Fax: +81.3.5545.0451

AUSTRALIA
BSD Robotics, A Luminex Company
Brisbane, Queensland
Tel: +61.7.3273.0273
Fax: +61.7.3273.0274

www.luminexcorp.com

info@luminexcorp.com